Nature Communications (Jan 2019)
ONECUT2 is a driver of neuroendocrine prostate cancer
- Haiyang Guo,
- Xinpei Ci,
- Musaddeque Ahmed,
- Junjie Tony Hua,
- Fraser Soares,
- Dong Lin,
- Loredana Puca,
- Aram Vosoughi,
- Hui Xue,
- Estelle Li,
- Peiran Su,
- Sujun Chen,
- Tran Nguyen,
- Yi Liang,
- Yuzhe Zhang,
- Xin Xu,
- Jing Xu,
- Anjali V. Sheahan,
- Wail Ba-Alawi,
- Si Zhang,
- Osman Mahamud,
- Ravi N. Vellanki,
- Martin Gleave,
- Robert G. Bristow,
- Benjamin Haibe-Kains,
- John T. Poirier,
- Charles M. Rudin,
- Ming-Sound Tsao,
- Bradly G. Wouters,
- Ladan Fazli,
- Felix Y. Feng,
- Leigh Ellis,
- Theo van der Kwast,
- Alejandro Berlin,
- Marianne Koritzinsky,
- Paul C. Boutros,
- Amina Zoubeidi,
- Himisha Beltran,
- Yuzhuo Wang,
- Housheng Hansen He
Affiliations
- Haiyang Guo
- Princess Margaret Cancer Centre, University Health Network
- Xinpei Ci
- The Vancouver Prostate Centre, Vancouver General Hospital and Department of Urologic Sciences, The University of British Columbia
- Musaddeque Ahmed
- Princess Margaret Cancer Centre, University Health Network
- Junjie Tony Hua
- Princess Margaret Cancer Centre, University Health Network
- Fraser Soares
- Princess Margaret Cancer Centre, University Health Network
- Dong Lin
- The Vancouver Prostate Centre, Vancouver General Hospital and Department of Urologic Sciences, The University of British Columbia
- Loredana Puca
- Weill Cornell Medicine
- Aram Vosoughi
- Weill Cornell Medicine
- Hui Xue
- The Vancouver Prostate Centre, Vancouver General Hospital and Department of Urologic Sciences, The University of British Columbia
- Estelle Li
- The Vancouver Prostate Centre, Vancouver General Hospital and Department of Urologic Sciences, The University of British Columbia
- Peiran Su
- Princess Margaret Cancer Centre, University Health Network
- Sujun Chen
- Princess Margaret Cancer Centre, University Health Network
- Tran Nguyen
- Princess Margaret Cancer Centre, University Health Network
- Yi Liang
- Princess Margaret Cancer Centre, University Health Network
- Yuzhe Zhang
- Princess Margaret Cancer Centre, University Health Network
- Xin Xu
- Princess Margaret Cancer Centre, University Health Network
- Jing Xu
- Princess Margaret Cancer Centre, University Health Network
- Anjali V. Sheahan
- Department of Oncologic Pathology, Dana-Farber Cancer Institute
- Wail Ba-Alawi
- Princess Margaret Cancer Centre, University Health Network
- Si Zhang
- Department of Experimental Therapeutics, BC Cancer Research Centre
- Osman Mahamud
- Princess Margaret Cancer Centre, University Health Network
- Ravi N. Vellanki
- Princess Margaret Cancer Centre, University Health Network
- Martin Gleave
- The Vancouver Prostate Centre, Vancouver General Hospital and Department of Urologic Sciences, The University of British Columbia
- Robert G. Bristow
- Princess Margaret Cancer Centre, University Health Network
- Benjamin Haibe-Kains
- Princess Margaret Cancer Centre, University Health Network
- John T. Poirier
- Memorial Sloan Kettering Cancer Center
- Charles M. Rudin
- Memorial Sloan Kettering Cancer Center
- Ming-Sound Tsao
- Princess Margaret Cancer Centre, University Health Network
- Bradly G. Wouters
- Princess Margaret Cancer Centre, University Health Network
- Ladan Fazli
- The Vancouver Prostate Centre, Vancouver General Hospital and Department of Urologic Sciences, The University of British Columbia
- Felix Y. Feng
- Department of Radiation Oncology, University of California at San Francisco
- Leigh Ellis
- Department of Oncologic Pathology, Dana-Farber Cancer Institute
- Theo van der Kwast
- Princess Margaret Cancer Centre, University Health Network
- Alejandro Berlin
- Princess Margaret Cancer Centre, University Health Network
- Marianne Koritzinsky
- Princess Margaret Cancer Centre, University Health Network
- Paul C. Boutros
- Department of Medical Biophysics, University of Toronto
- Amina Zoubeidi
- The Vancouver Prostate Centre, Vancouver General Hospital and Department of Urologic Sciences, The University of British Columbia
- Himisha Beltran
- Weill Cornell Medicine
- Yuzhuo Wang
- The Vancouver Prostate Centre, Vancouver General Hospital and Department of Urologic Sciences, The University of British Columbia
- Housheng Hansen He
- Princess Margaret Cancer Centre, University Health Network
- DOI
- https://doi.org/10.1038/s41467-018-08133-6
- Journal volume & issue
-
Vol. 10,
no. 1
pp. 1 – 13
Abstract
Neuroendocrine prostate cancer (NEPC) is characterized by loss of androgen receptor (AR) signaling during neuroendocrine transdifferentiation, resulting in resistance to AR-targeted therapy. Here they report ONECUT2 to drive NEPC tumorigenesis via regulation of hypoxia signaling and tumor hypoxia, and find hypoxia directed therapy to be effective in NEPC.
